Forest Laboratories, Inc. (FRX) Submits A New Drug Application For Nebivolol And Valsartan Combination In Hypertension
2/27/2014 9:51:52 AM
NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for a fixed dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.
Help employers find you! Check out all the jobs and post your resume.
comments powered by